# Innolake Biopharm

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/innolake-biopharm

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.innolakebio.com/
- Total disclosed funding: $14M
- Latest round: Series A (Jun 5, 2023)
- Investors on record: 3

## About

Established in 2020 and based in Hangzhou, China, Innolake Biopharm (Hangzhou) Co., Ltd., trading as Innolake Biopharm, is a medical company that focuses on the research and development of therapeutics in the areas of oncology and autoimmune, which was recognized as a Chinese Next Unicorn enterprise and listed in 2021 China Biopharmaceutical Industry Innovation Top100 List. It has a branch and business operation office in Shanghai. Dr. Mingde Xia, the Chairman, CEO, and co-founder, served as director of the Johnson & Johnson Group and worked at China Pharmaceutical University and Yale University. He is also a director of the US-China Pharmaceutical Association (SAPA).  In October 2025, Innolake Biopharm raised a venture funding from returning investor Zbjl Capital.

The company engages in research and developing drugs for tumors and immune system diseases. It has established a production pipeline that includes small molecules, therapeutic antibodies, and ADC.

## Funding rounds

- Series A, Jun 5, 2023, $14M — Hangzhou Economic and Technological Development Area, Yaoming Biology fund, Zbjl Capital

## Investors

- Hangzhou Economic and Technological Development Area — Series A
- Yaoming Biology fund — Series A
- Zbjl Capital (https://capitalatlas.ai/funds/zbjl-capital) — Series A